DHEA Supplementation and Thyroid Tumor Risk
Based on current evidence, long-term DHEA supplementation does not appear to increase the risk of thyroid tumors in humans, though long-term safety data remain insufficient to recommend routine use.
Evidence Assessment
Human Epidemiological Data
The most direct evidence comes from a population-based prospective case-control study that examined prediagnostic serum DHEA-S concentrations in 113 thyroid cancer cases matched with controls 1. This study found no significant association between physiological DHEA-S levels and thyroid cancer risk, including in the subgroup with papillary thyroid cancer. This suggests that DHEA within normal physiological ranges does not increase thyroid cancer risk.
Animal Studies Show Protective Effects
Interestingly, animal research demonstrates the opposite relationship—DHEA appears to have chemopreventive properties against thyroid tumors:
- DHEA inhibited chemically-induced thyroid tumor development in rats 2
- Synthetic DHEA analogs showed broad-spectrum tumor prevention including thyroid, lung, liver, and skin cancers 3
However, these studies used pharmacological doses far exceeding typical supplementation levels, limiting their applicability to human use.
Guideline Recommendations Against Routine Use
The Endocrine Society explicitly recommends against generalized DHEA use due to inadequate indications and lacking evidence of long-term safety 4. This recommendation is graded 1|⊕⊕○○ (strong recommendation, very low-quality evidence).
Limited Approved Indications
DHEA may only be considered in specific contexts 5:
- Women with primary adrenal insufficiency (PAI) experiencing persistent low libido, depressive symptoms, or low energy despite optimized glucocorticoid/mineralocorticoid replacement
- Trial period of 6 months; discontinue if no sustained benefit
- Dosing: 25-50 mg daily, monitored by morning DHEAS levels
Notably, even in these limited scenarios, guidelines acknowledge that "studies on long-term outcomes of chronic DHEA supplementation are lacking" 5.
Critical Safety Gaps
The evidence reveals several important caveats:
- No long-term human safety studies exist for DHEA supplementation 4, 5
- The single human study examined endogenous DHEA-S levels, not exogenous supplementation 1
- Animal protective effects occurred at supraphysiological doses not relevant to human supplementation
- DHEA use in cancer survivors (particularly hormone-sensitive cancers) has insufficient safety data 6, 7
Special Populations Requiring Caution
- Breast cancer survivors: DHEA should be used cautiously or avoided, especially with aromatase inhibitor therapy, as vaginal DHEA increases circulating androgens that may impact AI activity 7
- Estrogen-dependent cancers: Safety not established 7
Clinical Bottom Line
While there is no evidence that DHEA supplementation increases thyroid tumor risk, the absence of evidence is not evidence of safety. The lack of long-term human studies, combined with guideline recommendations against routine use, means DHEA should only be considered in specific clinical scenarios (primarily adrenal insufficiency) with appropriate monitoring.
For individuals considering DHEA supplementation without a clear medical indication, the prudent approach is to avoid it given the insufficient long-term safety data and lack of proven benefit for most indications 4.